Madrigal spends $255 million on multiple MASH drug deals to complement Rezdiffra

Madrigal Pharmaceuticals is expanding its MASH pipeline by acquiring several assets that could be used alongside its lead candidate, Rezdiffra. In early 2026 the company paid $50 million to Pfizer for the rights to a DGAT2 inhibitor and followed that with a $60 million purchase of six preclinical siRNA programs from Ribo Life Science and its Swedish affiliate Ribocure.

In May, Madrigal paid $25 million upfront to Arrowhead Pharmaceuticals for a phase‑1 RNA interference therapeutic that had previously been turned down by another firm. Early data suggest the drug may lower liver fat in patients with a specific genetic mutation that appears in about 30% of MASH cases.

The company also licensed a preclinical GLP‑1 agonist from China’s CSPC Pharmaceutical for $120 million upfront last year. Together, these deals give Madrigal a broader portfolio of candidates that could be combined with Rezdiffra to address the unmet need in metabolic dysfunction‑associated steatohepatitis.